Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release

Mitsuko Takenaga, Tsutomu Ishihara, Yuki Ohta, Yukie Tokura, Akemi Hamaguchi, Rie Igarashi, Tohru Mizushima

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effect of Nano PGE1 (nanoparticles containing prostaglandin E1) on spinal cord injury (SCI) was investigated in rat model. Nano PGE1 significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE1 was comparable with successive treatment of Lipo PGE1, and was superior to single treatment of Lipo PGE1.Distribution study revealed that Nano PGE1 sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE1 was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE1 were detected in Nano PGE1-treated injured spinal cord as compared with that in normal ones. Nano PGE1-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE1 had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE1 to the injured spinal cord. The sustained release of PGE1 would have increased HGF production, and both would have promoted cell survival and endogenous repair.

Original languageEnglish
Pages (from-to)249-254
Number of pages6
JournalJournal of Controlled Release
Volume148
Issue number2
DOIs
Publication statusPublished - 2010 Dec 1
Externally publishedYes

Fingerprint

Alprostadil
Spinal Cord Injuries
Nanoparticles
Spinal Cord
Cell Survival

Keywords

  • Basso Beattie Bresnahan (BBB)
  • Nanoparticles
  • Prostaglandin E (PGE)
  • Spinal cord injury (SCI)

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release. / Takenaga, Mitsuko; Ishihara, Tsutomu; Ohta, Yuki; Tokura, Yukie; Hamaguchi, Akemi; Igarashi, Rie; Mizushima, Tohru.

In: Journal of Controlled Release, Vol. 148, No. 2, 01.12.2010, p. 249-254.

Research output: Contribution to journalArticle

Takenaga, Mitsuko ; Ishihara, Tsutomu ; Ohta, Yuki ; Tokura, Yukie ; Hamaguchi, Akemi ; Igarashi, Rie ; Mizushima, Tohru. / Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release. In: Journal of Controlled Release. 2010 ; Vol. 148, No. 2. pp. 249-254.
@article{64e16db380ab49e99fc97bca5fbfa659,
title = "Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release",
abstract = "The effect of Nano PGE1 (nanoparticles containing prostaglandin E1) on spinal cord injury (SCI) was investigated in rat model. Nano PGE1 significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE1 was comparable with successive treatment of Lipo PGE1, and was superior to single treatment of Lipo PGE1.Distribution study revealed that Nano PGE1 sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE1 was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE1 were detected in Nano PGE1-treated injured spinal cord as compared with that in normal ones. Nano PGE1-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE1 had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE1 to the injured spinal cord. The sustained release of PGE1 would have increased HGF production, and both would have promoted cell survival and endogenous repair.",
keywords = "Basso Beattie Bresnahan (BBB), Nanoparticles, Prostaglandin E (PGE), Spinal cord injury (SCI)",
author = "Mitsuko Takenaga and Tsutomu Ishihara and Yuki Ohta and Yukie Tokura and Akemi Hamaguchi and Rie Igarashi and Tohru Mizushima",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.jconrel.2010.08.003",
language = "English",
volume = "148",
pages = "249--254",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release

AU - Takenaga, Mitsuko

AU - Ishihara, Tsutomu

AU - Ohta, Yuki

AU - Tokura, Yukie

AU - Hamaguchi, Akemi

AU - Igarashi, Rie

AU - Mizushima, Tohru

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The effect of Nano PGE1 (nanoparticles containing prostaglandin E1) on spinal cord injury (SCI) was investigated in rat model. Nano PGE1 significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE1 was comparable with successive treatment of Lipo PGE1, and was superior to single treatment of Lipo PGE1.Distribution study revealed that Nano PGE1 sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE1 was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE1 were detected in Nano PGE1-treated injured spinal cord as compared with that in normal ones. Nano PGE1-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE1 had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE1 to the injured spinal cord. The sustained release of PGE1 would have increased HGF production, and both would have promoted cell survival and endogenous repair.

AB - The effect of Nano PGE1 (nanoparticles containing prostaglandin E1) on spinal cord injury (SCI) was investigated in rat model. Nano PGE1 significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE1 was comparable with successive treatment of Lipo PGE1, and was superior to single treatment of Lipo PGE1.Distribution study revealed that Nano PGE1 sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE1 was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE1 were detected in Nano PGE1-treated injured spinal cord as compared with that in normal ones. Nano PGE1-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE1 had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE1 to the injured spinal cord. The sustained release of PGE1 would have increased HGF production, and both would have promoted cell survival and endogenous repair.

KW - Basso Beattie Bresnahan (BBB)

KW - Nanoparticles

KW - Prostaglandin E (PGE)

KW - Spinal cord injury (SCI)

UR - http://www.scopus.com/inward/record.url?scp=78649313812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649313812&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.08.003

DO - 10.1016/j.jconrel.2010.08.003

M3 - Article

VL - 148

SP - 249

EP - 254

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -